Literature DB >> 11237555

Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys.

M Mihara1, M Kotoh, N Nishimoto, Y Oda, E Kumagai, N Takagi, K Tsunemi, Y Ohsugi, T Kishimoto, K Yoshizaki, Y Takeda.   

Abstract

In the present study, we demonstrated the anti-arthritic effect of humanized anti-human IL-6 receptor (IL-6R) antibody, MRA, in cynomolgus monkey. MRA can react with monkey IL-6R and block signal transduction of IL-6. Collagen-induced arthritis (CIA) was induced by twice immunizing with bovine type II collagen (CII) emulsified with complete adjuvant. MRA was intravenously injected once a week, from the day of the first collagen immunization, for 13 weeks. The symptoms of arthritis were evaluated using a visual scoring system and radiography. Inflammatory parameters (C-reactive protein (CRP), fibrinogen, and erythrocyte sedimentation rate (ESR) and concentrations of anti-CII antibody, anti-MRA antibody, and MRA were monitored regularly. At the end of the study, histological evaluation was carried out. MRA, at a dose of 10 mg/kg, gave rise to statistically significant suppression. The elevation of serum CRP and fibrinogen levels and ESR were also inhibited. Furthermore, radiographic and histological examination showed that MRA treatment suppressed joint destruction. Our results demonstrate that IL-6 plays an important role in monkey CIA and that MRA may be an attractive agent for the treatment of rheumatoid arthritis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237555     DOI: 10.1006/clim.2000.4989

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  28 in total

1.  Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.

Authors:  E Choy
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.

Authors:  Martin S Zand; Thuong Vo; Tina Pellegrin; Raymond Felgar; Jane L Liesveld; Jainulabdeen J Ifthikharuddin; Camille N Abboud; Ignacio Sanz; Jennifer Huggins
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

3.  Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.

Authors:  Misato Hashizume; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2008-09-20       Impact factor: 2.631

4.  Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5.

Authors:  Courtney Gray-McGuire; Ritwik Sinha; Sudha Iyengar; Christopher Millard; Benjamin A Rybicki; Robert C Elston; Michael C Iannuzzi
Journal:  Hum Genet       Date:  2006-08-04       Impact factor: 4.132

5.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

6.  Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis.

Authors:  K Bendtzen; P R Hansen; K Rieneck
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  Hepcidin production in response to iron is controlled by monocyte-derived humoral factors.

Authors:  Yusuke Sasaki; Yasushi Shimonaka; Katsuya Ikuta; Takaaki Hosoki; Katsunori Sasaki; Yoshihiro Torimoto; Hirotaka Kanada; Yoshiyuki Moriguchi; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2013-12-01       Impact factor: 2.490

Review 8.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 9.  Advances in research on animal models of rheumatoid arthritis.

Authors:  Yiping Hu; Wenxiang Cheng; Wenhong Cai; Ye Yue; Jinchao Li; Peng Zhang
Journal:  Clin Rheumatol       Date:  2012-08-11       Impact factor: 2.980

10.  Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.

Authors:  Misato Hashizume; Yasushi Uchiyama; Naoto Horai; Naohisa Tomosugi; Masahiko Mihara
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.